Routine Generation of Powder Samples from HPLC Fractions
Genevac reports that its HT Series II Evaporator using the Fast Lyophilisation, or LyoSpeed process is enabling a growing number of pharmaceutical labs to routinely dry HPLC fraction samples to a powder form, such that the samples can then be accurately weighed, easily sub-sampled and redissolved.
When working with certain HPLC solvents, such as water and acetonitrile, a fully dried result can be hard to achieve due to interactions with the dissolved sample — esulting in the formation of a gum or oil.
To provide a rapid, high-throughput alternative to freeze drying HPLC purification fractions — Genevac developed its proprietary fast lyophilisation (LyoSpeed) methodology for use on the HT Series II Evaporators. Although LyoSpeed works well for most hydrophilic samples, difficulties may arise where the sample cannot dissolve in only water. In such situations, when the organic solvent is removed, the sample crashes out forming an oil which until now required further processing to achieve the desired dry powder form. For such samples and to improve LyoSpeed results generally — Genevac developed the SuperCool 75 which chills to -75 ºC and operates at higher power than any other commercially available condenser.
Customer trials have shown that the Genevac HT Series II Evaporator/SuperCool 75 combination produces powdered lyophilisation samples using the LyoSpeed methodology from even the most difficult to handle samples with a success rate as high as 95%
For further information please visit www.genevac.com/en/
Related News
-
News Swiss pharma industry warns US tariffs could harm global patient care
The Swiss pharmaceutical sector has raised alarms over new US tariffs on medicines, warning of disrupted supply chains, increased costs, and delayed innovation, all of which could jeopardise patient access to essential treatments worldwide.
-
News Women in Pharma: CPHI India – India’s Pharmaceutical Industry and Gender Inclusion Challenges
India’s pharmaceutical industry has emerged as a significant player in the global market, valued at USD 50 billion in FY 2023-2024, according to Frost & Sullivan’s analysis. This sector encompasses a diverse portfolio, including drugs, vacc... -
News Biogen acquires Apellis Pharmaceuticals to boost immunology and rare disease profile
Biogen Inc. has announced its acquisition of Apellis Pharmaceuticals, Inc., a move that is set to significantly enhance its growth portfolio in immunology and rare diseases. The agreement, valued at approximately US$5.6 billion, will see Biogen purchas... -
News Gilead Sciences acquires Ouro Medicines for over US$2 billion
Gilead Sciences confirms a deal to take over Ouro Medicines, adding to a portfolio of therapies for autoimmune diseases.
-
News Women in Pharma: Advancing Women's Health
Discover the latest innovations in technologies and therapeutics that are revolutionising women's health in our latest CPHI Online Women in Pharma infographic.
-
News CPHI Pharma Awards 2026: Recognising Excellence in an Evolving Industry
Submissions now open — deadline May 16
-
News Dr Reddy's to launch generic semaglutide in India
Dr Reddy’s Laboratories, one of India’s leading pharmaceutical companies, is preparing to launch a generic version of semaglutide, branded as Obeda, in March. Obeda is expected to provide a more affordable alternative to Ozempic a... -
News Frontier Biotech and GSK Forge RNA Therapy Partnership
Frontier Biotechnologies and GSK have entered a global licensing agreement to advance small interfering RNA (siRNA) therapeutics. This collaboration grants GSK exclusive rights to develop and commercialise two promising siRNA candidates, marking a mile...